Abivax SA has 11 Schedule 13D or 13G filings on record since 2025-07-31. 2 holders' latest filing reports 5% or more of ordinary shares, par value euro 0.01 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Chen Yu | 7% | 6,007,834 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Invus Public Equities, L.P. | 6% | 4,790,187 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
| Deep Track Capital, LP | 4.78% | 3,480,144 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Sofinnova Crossover I SLP | 4.3% | 3,535,843 | SCHEDULE 13D/A, 2026-07-06 | 2026-07-02 |
| Venrock Healthcare Capital Partners III, L.P. | 0.8% | 576,729 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
Purpose of Transaction (Item 4)
Sofinnova Crossover I SLP
Item 4 of the Schedule 13D is hereby amended and supplemented as follows: SC sold the amounts of ADS and Ordinary Shares on the date and at the prices set forth below in open market transactions on NASDAQ and Euronext. All daily sales of the shares were sold in multiple transactions at varying prices. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each weighted average price set forth in this Schedule 13D. June 30, 2026: -500,000 ADSs at a weighted average price of $132.7347 per share. July 1, 2026: -25,000 ADSs at a weighted average price of $134.2377 per share. July 2, 2026: -275,000 ADSs at a weighted average price of $140.9365 per share.* -35,469 Ordinary Shares at a weighted average price of $144.2752 per share.* July 3, 2026: -25,000 Ordinary Shares at a weighted average price of $156.2041 per share.* -39,531 Ordinary Shares at a weighted average price of $155.0654 per share.* July 6, 2026: -3,195 Ordinary Shares at a weighted average price of $155.0436 per share.* * Transaction completed in Euros. Price per share converted to USD at an exchange rate of $1.1448 as of July 3, 2026. All of the Ordinary Shares that are held of record by the Reporting Persons as reported herein were acquired for investment purposes. The Reporting Persons retain the right to change their investment intent, from time …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-07-06; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-31 | Sofinnova Crossover I SLP | 11.4% | SCHEDULE 13D/A |
| 2025-08-14 | Deep Track Capital, LP | 4.78% | SCHEDULE 13G/A |
| 2025-10-30 | Sofinnova Crossover I SLP | 9.4% | SCHEDULE 13D/A |
| 2025-11-14 | Chen Yu | 9.1% | SCHEDULE 13G/A |
| 2025-11-14 | Venrock Healthcare Capital Partners III, L.P. | 0.8% | SCHEDULE 13G/A |
| 2026-01-14 | Sofinnova Crossover I SLP | 7.7% | SCHEDULE 13D/A |
| 2026-02-13 | Invus Public Equities, L.P. | 5% | SCHEDULE 13G/A |
| 2026-05-11 | Sofinnova Crossover I SLP | 6.7% | SCHEDULE 13D/A |
| 2026-07-06 | Sofinnova Crossover I SLP | 4.3% | SCHEDULE 13D/A |
| 2026-08-13 | Invus Public Equities, L.P. | 6% | SCHEDULE 13G/A |
| 2026-08-14 | Chen Yu | 7% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Abivax SA. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.